New treatment options for infections caused by increasingly antimicrobial-resistant Neisseria gonorrhoeae

Expert Review of Anti-Infective Therapy

Volumn 14, Issue 2, 2016, Pages 243-256

  Lee, Hyukmin ^a   Lee, Kyungwon ^b   Chong, Yunsop ^b  

^a Kwandong University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Azithromycin; Ceftriaxone; Combination therapy; Dual therapy; ETX0914; Neisseria gonorrhoeae; New treatment options; Solithromycin; Spectinomycin

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; BACTERIAL VACCINE; CEFIXIME; CEFTRIAXONE; DOXYCYCLINE; ERTAPENEM; FOSFOMYCIN; GEMIFLOXACIN; GENTAMICIN; MOXIFLOXACIN; RIFAMPICIN; SITAFLOXACIN; SOLITHROMYCIN; SPECTINOMYCIN; TIGECYCLINE; ZOLIFLODACIN; BARBITURIC ACID DERIVATIVE; MACROLIDE; SPIRO COMPOUND; TRIAZOLE DERIVATIVE;

ANTIBIOTIC RESISTANCE; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; GONORRHEA; HUMAN; INFECTION CONTROL; NEISSERIA GONORRHOEAE; NONHUMAN; REVIEW; TREATMENT OUTCOME; COMBINATION DRUG THERAPY; MICROBIOLOGY; NEISSERIACEAE INFECTIONS; PHARYNGITIS; PHYSIOLOGY;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BARBITURATES; CEFTRIAXONE; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; GONORRHEA; HUMANS; MACROLIDES; NEISSERIA GONORRHOEAE; NEISSERIACEAE INFECTIONS; PHARYNGITIS; SPECTINOMYCIN; SPIRO COMPOUNDS; TRIAZOLES;

EID: 84957624350     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.2016.1134315     Document Type: Review

References (101)

1. Elias J, Frosch M, Vogel U. Neisseria, Jorgensen JH, Pfaller MA, et al., editors. Manual of clinical microbiology. 11th ed. Washington (DC):American Society for Microbiology Press; 2015. p.635-21
2. Chacko MR, Wiemann CM, Smith PB. Chlamydia and gonorrhea screening in asymptomatic young women. J Pediatr Adolesc Gynecol. 2004;17:169-178
3. Wiesenfeld HC, Hillier SL, Krohn MA, et al. Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. Obstet Gynecol. 2002;100:456-463
4. Holmes KK, Counts GW, Beaty HN. Disseminated gonococcal infection. Ann Intern Med. 1971;74:979-993
5. Belkacem A, Caumes E, Ouanich J, et al. Changing patterns of disseminated gonococcal infection in France: cross-sectional data 2009-2011. Sex Transm Infect. 2013;89:613-615
6. World Health Organization (WHO). Global incidence and prevalence of selected curable sexually transmitted infections-2008. Geneva: World Health Organization; 2012. p. 2012
7. Svensson L, Weström L, Ripa KT, et al. Differences in some clinical and laboratory parameters in acute salpingitis related to culture and serologic findings. Am J Obstet Gynecol. 1980;138:1017-1021
8. Westrom LV. Sexually transmitted diseases and infertility. Sex Transm Dis. 1994;21:532-537
9. Westrom L. Effects of acute pelvic inflammatory disease on infertility. Am J Obstetrics Gynecol. 1975;121:707
10. Ndowa F, Lusti-Narasimhan M. The threat of untreatable gonorrhoea: implications and consequences for reproductive and sexual morbidity. Reprod Health Matters. 2012;20:76-82
11. Ebrahim SH, McKenna MT, Marks JS. Sexual behaviour: related adverse health burden in the United States. Sex Transm Infect. 2005;81:38-40
12. Murray CJ, Barber RM, Foreman KJ, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lanet. 2015;386:2145-2191
13. Owusu-Edusei K Jr, Chesson HW, Gift TL, et al. The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex Transm Dis. 2013;40:197-201
14. Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States, 2013. Centers for Disease Control and Prevention (CDC); 2013 [cited 2015 Oct 29]. Available from: http://www.cdc.gov/ drugresistance/pdf/ar-threats-2013-508.pdf
15. Epstein E. Failure of penicillin in treatment of acute gonorrhea in American troops in Korea. J Am Med Assoc. 1959;169:1055-1059
16. Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev. 2014;27:587-613
17. Bignell C, Unemo M. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2013;24:85-92
18. Australasian Sexual Health Alliance (ASHA). Australian STI management guidelines for use in primary care. [cited 2015 Oct 29]. Available from: www.sti.guidelines.org.au/sexuallytransmissible-infections/gonorrhoea#management
19. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(03):1-137
20. Public Health Agency of Canada. Canadian guidelines on sexually transmitted infections. Gonococcal Infections Chapter; 2013 cited 2015 Oct 29]. Available from: www. phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/assets/pdf/sec tion-5-6-eng.pdf
21. [cited 2015 Oct 29]. Available from: http://jssti.umin.jp/pdf/ guideline-2011.pdf 2011
22. World Health Organization. Guidelines for the management of sexually transmitted diseases. World Health Organization; 2003. ISBN: 92 4 154626 3. Available from: http://www.who.int/hiv/pub/sti/en/STIGuidelines2003. pdf
23. Trebach JD, Chaulk CP, Page KR, et al. Neisseria gonorrhoeae and Chlamydia trachomatis among women reporting extragenital exposures. Sex Transm Dis. 2015;42:233-239
24. Wong HT, Lee KC, Chan DP. Community-based sexually transmitted infection screening and increased detection of pharyngeal and urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infections in female sex workers in Hong Kong. Sex Transm Dis. 2015;42:185-191
25. Wada K, Uehara S, Mitsuhata R, et al. Prevalence of pharyngeal Chlamydia trachomatis and Neisseria gonorrhoeae among heterosexual men in Japan. J Infect Chemother. 2012;18:729-733
26. Barbee LA, Khosropour CM, Dombrowski JC, et al. An estimate of the proportion of symptomatic gonococcal, chlamydial and non-gonococcal non-chlamydial urethritis attributable to oral sex among men who have sex with men: a case-control study. Sex Transm Infect. 2015 Aug 21;pii: sextrans-2015-052214. doi:10.1136/sextrans-2015-052214. [Epub ahead of print]
27. World Health Organization (WHO), Department of Reproductive Health and Research. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. Geneva (Switzerland): WHO; 2012. p. 1-36
28. Unemo M. Current and future antimicrobial treatment of gonorrhoea\-The rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infect Dis. 2015;15:364
29. Ohnishi M, Golparian D, Shimuta K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea? Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother. 2011;55:3538-3545
30. Unemo M, Golparian D, Nicholas R, et al. High-level cefixime-and ceftriaxone-resistant N. gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother. 2012;56:1273-1280
31. Cámara J, Serra J, Ayats J, et al. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother. 2012;67:1858-1860
32. Tapsall J, Read P, Carmody C, et al. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. J Med Microbiol. 2009;58:683-687
33. Chisholm SA, Mouton JW, Lewis DA, et al. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J Antimicrob Chemother. 2010;65:2141-2148
34. Chen YM, Stevens K, Tideman R, et al. Failure of 500 mg of ceftriaxone to eradicate pharyngeal gonorrhoea, Australia. J Antimicrob Chemother. 2013;68:1445-1447
35. Golparian D, Ohlsson A, Janson H, et al. Four treatment failures of pharyngeal gonorrhoea with ceftriaxone (500 mg) or cefotaxime (500 mg), Sweden, 2013 and 2014. Euro Surveill. 2014;31(30):19
36. Waugh MA. Open study of the safety and efficacy of a single oral dose of azithromycin for the treatment of uncomplicated gonorrhoea in men and women. J Antimicrob Chemother. 1993;31(Suppl ):193-198
37. Handsfield HH, Dalu DA, Martin DH, et al. Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Sex Transm Dis. 1994;21:107-111
38. Young H, Palmer HM. Gonococcal antibiotic surveillance in Scotland (GASS): prevalence, pattern and trends in 2005. HPS Wkly. 2006;40:54-55
39. Bignell C, Garley J. Azithromycin in the treatment of infection with Neisseria gonorrhoeae. Sex Trans Infect. 2010;86:422-426
40. Yasuda M, Ito S, Kido A, et al. A single 2 g oral dose of extended-release azithromycin for treatment of gonococcal urethritis. J Antimicrob Chemother. 2014;69:3116-3118
41. Roberts MC, Chung WO, Roe D, et al. Erythromycin-resistant Neisseria gonorrhoeae and oral commensal Neisseria spp. carry known rRNA methylase genes. Antimicrob Agents Chemother. 1999;43:1367-1372
42. Ng LK, Martin I, Liu G, et al. Mutation in 23S rRNA associated with macrolide resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2002;46:3020-3025
43. Chisholm SA, Dave J, Ison CA. High-level azithromycin resistance occurs in Neisseria gonorrhoeae as a result of a single point mutation in the 23S rRNA genes. Antimicrob Agents Chemother. 2010;54:3812-3816
44. Morita-Ishihara T, Unemo M, Furubayashi K, et al. Treatment failure with 2 g of azithromycin (extended-release formulation) in gonorrhoea in Japan caused by the international multidrug-resistant ST1407 strain of Neisseria gonorrhoeae. J Antimicrob Chemother. 2014;69:2086-2090
45. Palmer HM, Young H, Winter A, et al. Emergence and spread of azithromycin-resistant Neisseria gonorrhoeae in Scotland. J Antimicrob Chemother. 2008;62:490-494
46. Starnino S, Stefanelli P. Neisseria gonorrhoeae Italian Study Group I. Azithromycin-resistant Neisseria gonorrhoeae strains recently isolated in Italy. J Antimicrob Chemother. 2009;63:1200-1204
47. Katz AR, Komeya AY, Soge OO, et al. Neisseria gonorrhoeae with high-level resistance to azithromycin: case report of the first isolate identified in the United States. Clin Infect Dis. 2012;54:841-843
48. Unemo M, Golparian D, Hellmark B. First three Neisseria gonorrhoeae isolates with high-level resistance to azithromycin in Sweden: a threat to currently available dual-antimicrobial regimens for treatment of gonorrhea? Antimicrob Agents Chemother. 2013;58:624-625
49. Stevens K, Zaia A, Tawil S, et al. Neisseria gonorrhoeae isolates with high-level resistance to azithromycin in Australia. J Antimicrob Chemother. 2015;70:1267-1268
50. Xue J, Ni C, Zhou H, et al. Occurrence of high-level azithromycin-resistant Neisseria gonorrhoeae isolates in China. J Antimicrob Chemother. 2015 Aug 27;70:3404-3405
51. Lynagh Y, Mac Aogáin M, Walsh A, et al. Detailed characterization of the first high-level azithromycin-resistant Neisseria gonorrhoeae cases in Ireland. J Antimicrob Chemother. 2015;70:2411-2413
52. Galimand M, Gerbaud G, Courvalin P. Spectinomycin resistance in Neisseria spp. due to mutations in 16S rRNA. Antimicrob Agents Chemother. 2000;44:1365-1366
53. Unemo M, Fasth O, Fredlund H, et al. Phenotypic and genetic characterization of the 2008WHONeisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J Antimicrob Chemother. 2009;63:1142-1151
54. Unemo M, Golparian D, Skogen V, et al. Neisseria gonorrhoeae strain with high-level resistance to spectinomycin due to a novel resistance mechanism (mutated ribosomal protein S5) verified in Norway. Antimicrob Agents Chemother. 2013;57:1057-1061
55. Ison CA, Littleton K, Shannon KP, et al. Spectinomycin resistant gonococci. Br Med J (Clin Res Ed). 1983;287:1827-1829
56. Easmon CS, Forster GE, Walker GD, et al. Spectinomycin as initial treatment for gonorrhoea. Br Med J. 1984;289:1032-1034
57. Boslego JW, Tramont EC, Takafuji ET, et al. Effect of spectinomycin use on the prevalence of spectinomycinresistant and penicillinase-producing Neisseria gonorrhoeae. N Engl J Med. 1987;317:272-278
58. Lee H, Hong SG, Soe Y, et al. Trends in antimicrobial resistance of Neisseria gonorrhoeae isolated from Korean patients from 2000 to 2006. Sex Transm Dis. 2011;38:1082-1086
59. Lee H, Unemo M, Kim HJ, et al. Emergence of decreased susceptibility and resistance to extended-spectrum cephalosporins in Neisseria gonorrhoeae in Korea. J Antimicrob Chemother. 2015;70:2536-2542
60. Moran JS. Treating uncomplicated Neisseria gonorrhoeae infections: is the anatomic site of infection important? Sex Transm Dis. 1995;22:39-47
61. Barbee LA, Dombrowski JC, Kerani R, et al. Effect of nucleic acid amplification testing on detection of extragenital gonorrhea and chlamydial infections in men who have sex with men sexually transmitted disease clinic patients. Sex Transm Dis. 2014;41:168-172
62. Walsh A, Rourke FO, Crowley B. Molecular detection and confirmation of Neisseria gonorrhoeae in urogenital and extragenital specimens using the Abbott CT/NG Real Time assay and an in-house assay targeting the porA pseudogene. Eur J Clin Microbiol Infect Dis. 2011;30:561-567
63. Felarca AB, Laqui EM, Ibarra LM. Gentamicin in gonococcal urethritis of Filipino males: dosage and response. J Infect Dis. 1971;124(Suppl):S287-292
64. Tan NJ, Rajan VS, Pang R, et al. Gentamicin in the treatment of infections due to penicillinase-producing gonococci. Br J Vener Dis. 1980;56:394-396
65. Hira SK, Attili VR, Kamanga J, et al. Efficacy of gentamicin and kanamycin in the treatment of uncomplicated gonococcal urethritis in Zambia. Sex Transm Dis. 1985;12:52-54
66. Olsen B, Lan PT, Golparian D, et al. Antimicrobial susceptibility and genetic characteristics of Neisseria gonorrhoeae isolates from Vietnam, 2011. BMC Infect Dis. 2013;13:40
67. Olsen B, Månsson F, Camara C, et al. Phenotypic and genetic characterisation of bacterial sexually transmitted infections in Bissau, Guinea-Bissau, West Africa: a prospective cohort study. BMJ Open. 2012;2:e000636
68. Chisholm SA, Quaye N, Cole MJ, et al. An evaluation of gentamicin susceptibility of Neisseria gonorrhoeae isolates in Europe. J Antimicrob Chemother. 2011;66:592-595
69. Daly CC, Hoffman I, Hobbs M, et al. Development of an antimicrobial susceptibility surveillance system for Neisseria gonorrhoeae in Malawi: comparison of methods. J Clin Microbiol. 1997;35:2985-2988
70. Brown LB, Krysiak R, Kamanga G, et al. Neisseria gonorrhoeae antimicrobial susceptibility in Lilongwe, Malawi, 2007. Sex Transm Dis. 2010;37:169-172
71. Dowell D, Kirkcaldy RD. Effectiveness of gentamicin for gonorrhoea treatment: systematic review and meta-analysis. Sex Transm Infect. 2012;88:589-594
72. Hathorn E, Dhasmana D, Duley L, et al. The effectiveness of gentamicin in the treatment of Neisseria gonorrhoeae: a systematic review. Syst Rev. 2014;3:104
73. Rodríguez A, Gallego A, Olay T, et al. Bacteriological evaluation of fosfomycin in clinical studies. Chemotherapy. 1977;23(Suppl 1):247-258
74. Dickgiesser N, Kuntz P. The activity of rosoxacin, fosfomycin, cefotiam, and spectinomycin on beta-lactamase producing Neisseria gonorrhoeae. Br J Vener Dis. 1984;60:154-156
75. Hauser C, Hirzberger L, Unemo M, et al. In vitro activity of fosfomycin alone and in combination with ceftriaxone or azithromycin against clinical Neisseria gonorrhoeae isolates. Antimicrob Agents Chemother. 2015;59:1605-1611
76. Unemo M, Golparian D, Limnios A, et al. In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea? Antimicrob Agents Chemother. 2012;56:3603-3609
77. Quaye N, Cole MJ, Ison CA. Evaluation of the activity of ertapenem against gonococcal isolates exhibiting a range of susceptibilities to cefixime. J Antimicrob Chemother. 2014;69:1568-1571
78. Deshpande LM, Gales AC, Jones RN. GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: preliminary guidelines and interpretive criteria. Int J Antimicrob Agents. 2001;18:29-35
79. Falagas ME, Karageorgopoulos DE, Dimopoulos G. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. Curr Drug Metab. 2009;10:13-21
80. Nix DE, Matthias KR. Should tigecyclinebe considered for urinary tract infections? A pharmacokinetic re-evaluation. J Antimicrob Chemother. 2010;65:1311-1312
81. Sato K, Hoshino K, Tanaka M, et al. Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob Agents Chemother. 1992;36:1491-1498
82. Hamasuna R, Yasuda M, Ishikawa K, et al. The second nationwide surveillance of the antimicrobial susceptibility of Neisseria gonorrhoeae from male urethritis in Japan, 2012-2013. J Infect Chemother. 2015;21:340-345
83. Tanaka M, Nakayama H, Haraoka M, et al. Susceptibilities of Neisseria gonorrhoeae isolates containing amino acid substitutions in GyrA, with or without substitutions in ParC, to newer fluoroquinolones and other antibiotics. Antimicrob Agents Chemother. 2000;44:192-195
84. Nakashima M, Uematsu T, Kosuge K, et al. Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimicrob Agents Chemother. 1995;39:170-174
85. Matsumoto T, Uchino K, Yamaguchi H, et al. Study on the safety and efficacy of sitafloxacin-results of the useresults survey. Jpn J Antibiot. 2011;64:319-337. Japanese
86. Furuya R, Nakayama H, Kanayama A, et al. In vitro synergistic effects of double combinations of beta-lactams and azithromycin against clinical isolates of Neisseria gonorrhoeae. J Infect Chemother. 2006;12:172-176
87. Furuya R, Koga Y, Irie S, et al. In vitro activities of antimicrobial combinations against clinical isolates of Neisseria gonorrhoeae. J Infect Chemother. 2013;19:1218-1220
88. Pereira R, Cole MJ, Ison CA. Combination therapy for gonorrhoea: in vitro synergy testing. J Antimicrob Chemother. 2013;68:640-643
89. Barbee LA, Soge OO, Holmes KK, et al. In vitro synergy testing of novel antimicrobial combination therapies against Neisseria gonorrhoeae. J Antimicrob Chemother. 2014;69:1572-1578
90. Wind CM, Vries HJC, Van Dam AP. Determination of in vitro synergy for dual antimicrobial therapy against resistant Neisseria gonorrhoeae using Etest and agar dilution. Int J Antimicrob Agents. 2015;45:305-308
91. Pettus K, Sharpe S, Papp JR. In vitro assessment of dual drug combinations to inhibit growth of Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2015;59:2443-2445
92. Kirkcaldy RD,Weinstock HS,Moore PC, et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis. 2014;59:1083-1091
93. Putnam SD, Castanheira M, Moet GJ, et al. CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram-negative bacteria. Diagn Microbiol Infect Dis. 2010;66:393-401
94. Mallegol J, Fernandes P, Seah C, et al. Determination of in vitro activity of solithromycin at different pHs and its intracellular activity tested against clinical isolates of Neisseria gonorrhoeae from a laboratory collection. Antimicrob Agents Chemother. 2013;57:4322-4328
95. Golparian D, Fernandes P, Ohnishi M, et al. In vitro activity of the new fluoroketolidesolithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatment option for gonorrhea? Antimicrob Agents Chemother. 2012;56:2739-2742
96. Hook EW, Golden M, Jamieson BD, et al. A Phase 2 Trial of Oral Solithromycin 1200 mg or 1000 mg as Single-Dose Oral Therapy for Uncomplicated Gonorrhea. Clin Infect Dis. 2015;61:1043-1048
97. Jacobsson S, Golparian D, Alm RA, et al. High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea. Antimicrob Agents Chemother. 2014;58:5585-5588
98. Huband MD, Bradford PA, Otterson LG, et al. In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria. Antimicrob Agents Chemother. 2015;59:467-474
99. Unemo M, Ringlander J, Wiggins C, et al. High In Vitro Susceptibility to the Novel Spiropyrimidinetrione ETX0914 (AZD0914) among 873 Contemporary Clinical Neisseria gonorrhoeae Isolates from 21 European Countries from 2012 to 2014. Antimicrob Agents Chemother. 2015;59:5220-5225
100. Jerse AE, Deal CD. Vaccine research for gonococcal infections: where are we? Sex Transm Infect. 2013;89(Suppl 4): iv63-8
101. Craig AP, Gray RT, Edwards JL, et al. The potential impact of vaccination on the prevalence of gonorrhea. Vaccine. 2015;33:4520-4525